Cyclerion Therapeutics heads into its May 15 earnings report with a borrow market that has loosened sharply — even as the cost to borrow remains extraordinarily high.
The most striking shift in the lending data is not the level but the direction. Short interest collapsed by roughly 98% over the past week to just 3,685 shares — effectively a rounding error at under 0.1% of the float. That dramatic unwind followed a period in early April when estimated short interest topped 1.6 million shares. Availability has moved with it: the borrow pool is no longer being stressed as it was through April, when the lending market repeatedly hit full capacity. Cost to borrow, however, remains punishing at 284% annualised — down from a peak near 508% in early April, but still reflecting a market where anyone holding a short position is paying dearly to do so. The ORTEX short score has pulled back to 59 from above 71 just two weeks ago, consistent with the broader unwinding of bearish positioning.
The stock's recent price action reflects a complicated few months. At $3.18, CYCN has gained 9% over the past month and nearly 1% on the week, following one of the most volatile earnings reactions in the data: the March 31 announcement triggered a 342% single-day gain, with the stock still up 141% five days later. That move is the dominant event in the historical record and represents a genuine discontinuity — prior prints produced modest single-digit moves. The April short-interest surge and subsequent collapse look inseparable from that episode, as traders positioned around and then retreated from the volatility. The enterprise value sits at approximately $8.3 million, underlining just how micro-cap this name is and how even small position changes can distort the lending data.
The institutional picture is thin but notable. FMR LLC (Fidelity) reported holding 649,547 shares — roughly 15% of the company — as of April 30, adding 644,807 shares in the most recent period. That is a near-fresh position and represents by far the largest institutional build in the data. Director Peter Hecht is the second-largest holder with 559,203 shares; his last insider purchase, in March 2025, was at $2.75, below the current price. Analyst coverage appears limited to a single stale buy-side target of $8.00 from early February, which is more than three months old and should be treated as indicative rather than current. The options market data predates 2024 and is not usable.
Thursday's print will test whether the operational story behind March's extraordinary reaction has staying power — or whether that move has already fully repriced whatever news the company is carrying into this quarter.
See the live data behind this article on ORTEX.
Open CYCN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
